DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/qm9dw8/multiple) has announced the addition of the "Multiple Sclerosis Market in the US 2015-2019" report to their offering.
This report covers the present scenario and the growth prospects of the multiple sclerosis market in the US for the period 2015-2019. To calculate the market size, the report considers revenue generated from sales of various drugs used in the treatment of multiple sclerosis.
Multiple sclerosis is a chronic, inflammatory medical condition, which results in demyelination, axonal transection, and neurodegeneration of the nerve cells of the brain and spinal cord. The immune system of the body targets the neurons within the CNS and damages the myelin sheath. It is a potentially debilitating disease, causing disruption in the communication and coordination functions of the body. The symptoms of multiple sclerosis differ widely, subject to the extent of damage and the number of neurons affected. Some of the symptoms observed are fatigue, numbness, spasticity, bladder dysfunction, cognitive changes, emotional changes, and depression. An individual with severe form of the disease can experience speech and movement problems.
The US FDA has approved certain disease-modifying drugs for treating various forms of multiple sclerosis. These drugs interact with the immune system to reduce the number of relapses. Copaxone (glatiramer acetate) by Teva Pharmaceutical, Avonex (interferon beta-1a) and Tysabri (natalizumab) by Biogen, Gilenya (fingolimod) by Novartis, and Betaseron (interferon beta-1b) by Bayer are some of the disease-modifying drugs indicated for the treatment of the disease. Daclizumab by Biogen and BAF312 by Novartis are disease-modifying drugs expected to be launched during the forecast period.
According to the report, in 2014, currently, medications that can produce the remission of multiple sclerosis in patients are absent. In addition, there are no established treatment procedures for multiple sclerosis. The available drugs in the market are only intended to modify the course of the disease and treat relapses. Some of the drugs are also meant for the symptomatic treatment of the patient and for managing emotional health. Thus, there is a lucrative space for companies that can address the issue of unmet medical needs in the market and develop drugs that can completely cure the disease.
Further, the report states that unknown disease etiology has made it difficult for researchers to develop drugs that can target its cause.
Multiple sclerosis can be broadly classified into four types:
On the basis of route of administration of the drugs, the market is grouped into the following categories:
On the basis of type of molecule of the drugs, the market is grouped into the following categories:
- Small Molecules
- Bayer AG
- Merck Serono
- Novartis AG
- Teva Pharmaceutical Industries Ltd.
Other Prominent Vendors
- AB Science
- Acorda Therapeutics
- Active Biotech
- F. Hoffmann-La Roche
- InnoBioscience Pharmaceuticals
- medDay Pharmaceuticals
- Mitsubishi Tanabe
- Opexa Therapeutics
- RedHill Biopharma
For more information visit http://www.researchandmarkets.com/research/qm9dw8/multiple